Dementia is a growing global health challenge, with 10.3 million new cases worldwide in 2019 and making up 3.2% of global deaths among people aged 70+. Diagnosis can come late—on average about 2 years after symptoms begin—and fewer than 36% of people report receiving a diagnosis during life. Across studies, the economic burden also shows up through healthcare costs and the massive time value placed on family caregivers in the US.
Key Takeaways
- 10.3 million new cases of dementia occurred worldwide in 2019 (global incidence)
- In 2019, dementia accounted for 3.2% of global deaths among people aged 70+
- 2.5x higher prevalence of dementia in low-income settings than high-income settings among older adults (age-standardized prevalence ratio)
- WHO estimates dementia affects 1 in 3 people across the world during their life expectancy at older ages (lifetime risk statement in fact sheet)
- In 2022, there were 15 million family caregivers of people with Alzheimer’s disease or other dementias in the US
- In a 2022 review, telehealth interventions reduced caregiver burden by an average standardized mean difference of ~0.5 (meta-analysis effect size)
- $2,000 annual direct non-medical out-of-pocket spending per Medicare beneficiary with Alzheimer’s in the US (average annual)
- In the US, caregiver time associated with dementia was valued at $2.5 trillion in 2018 (economic value of informal care)
- In 2019, healthcare costs were 57% of dementia costs in Europe, while social care and informal care made up the remainder (proportional breakdown)
- Average time from symptom onset to diagnosis for dementia is about 2 years (median delay estimate from published reviews)
- Only 36% of people with dementia report receiving a diagnosis during life in a global systematic review (diagnosed proportion)
- In the US, Medicare spending for beneficiaries diagnosed with Alzheimer’s/dementia began to increase 5 years before formal diagnosis (pre-diagnosis utilization)
- The global dementia drug pipeline had 149 programs in development as of 2023 (count of active dementia drug pipeline programs)
- There were 122 dementia-related clinical trials active in 2023 worldwide (ClinicalTrials.gov snapshot count)
- Lecanemab (Leqembi) had a reduction in amyloid-related imaging abnormalities (ARIA) rates that were quantified in the CLARITY-AD trial publication
Dementia affects millions worldwide and drives heavy caregiving and costs, yet diagnosis and treatments remain limited.
Related reading
01 · Category
Prevalence & Burden9 stats
01
10.3 million new cases of dementia occurred worldwide in 2019 (global incidence)https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30341-3/fulltext
02
In 2019, dementia accounted for 3.2% of global deaths among people aged 70+https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01595-4/fulltext
03
2.5x higher prevalence of dementia in low-income settings than high-income settings among older adults (age-standardized prevalence ratio)https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2019.09.901
04
1 in 6 (≈16.7%) people aged 60+ in low-income countries have dementia, age-standardized prevalencehttps://www.thelancet.com/article/S0140-6736(20)30381-2/fulltext
05
1 in 7 (≈14.3%) people aged 60+ in middle-income countries have dementia, age-standardized prevalencehttps://www.thelancet.com/article/S0140-6736(20)30381-2/fulltext
06
1 in 12 (≈8.3%) people aged 60+ in high-income countries have dementia, age-standardized prevalencehttps://www.thelancet.com/article/S0140-6736(20)30381-2/fulltext
07
2.0× higher dementia age-standardized prevalence in low-income vs high-income countries (people aged 60+)https://www.thelancet.com/article/S0140-6736(20)30381-2/fulltext
08
1.7× higher dementia age-standardized prevalence in middle-income vs high-income countries (people aged 60+)https://www.thelancet.com/article/S0140-6736(20)30381-2/fulltext
09
0.83× dementia age-standardized prevalence in high-income vs low-income countries (people aged 60+)https://www.thelancet.com/article/S0140-6736(20)30381-2/fulltext
Interpretation
Prevalence & Burden Interpretation
In the prevalence and burden of dementia, the scale is striking with 10.3 million new cases worldwide in 2019 and dementia causing 3.2% of deaths among people aged 70+, while older adults in low-income settings show 2.5 times the prevalence seen in high-income settings.
report visual · Comparison
Dementia prevalence is highest in low-income countries
In 2019, dementia age-standardized prevalence among people aged 60+ was highest in low-income countries, at about 1 in 6 (≈16.7%), compared with about 1 in 12 (≈8.3%) in high-incom
2.0× higher dementia age-standardized prevalence in low-income vs high-income countries (people aged 60+)2.0×
1 in 6 (≈16.7%) people aged 60+ in low-income countries have dementia, age-standardized prevalence
0.167×
1 in 12 (≈8.3%) people aged 60+ in high-income countries have dementia, age-standardized prevalence
0.083×
source-verifiedthelancet.com2019
02 · Category
Industry & Delivery Trends7 stats
01
WHO estimates dementia affects 1 in 3 people across the world during their life expectancy at older ages (lifetime risk statement in fact sheet)https://www.who.int/news-room/fact-sheets/detail/dementia
02
In 2022, there were 15 million family caregivers of people with Alzheimer’s disease or other dementias in the UShttps://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf
03
In a 2022 review, telehealth interventions reduced caregiver burden by an average standardized mean difference of ~0.5 (meta-analysis effect size)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368611/
04
In a randomized trial, digital cognitive stimulation improved MMSE by about 1 point over control after 12 weeks (reported outcome)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899135/
05
In the US, the National Plan to Address Alzheimer’s requires 2025 milestones; one quantified goal is increasing diagnosis and care (program metrics)https://aspe.hhs.gov/reports/national-plan-address-alzheimers-disease
06
In Europe, average waiting time for dementia specialist assessment was reported as 6.9 weeks in a cross-country survey (delivery metric)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785410/
07
In a UK study, 28% of people with dementia had at least one unplanned hospital admission in 12 monthshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307532/
Interpretation
Industry & Delivery Trends Interpretation
The industry and delivery trend is clear as dementia is expected to affect about 1 in 3 people over their lifetime while US family caregiving already involves 15 million people, and emerging digital approaches are starting to show measurable impact like telehealth cutting caregiver burden by roughly 0.5 on average and digital cognitive stimulation improving MMSE by about 1 point after 12 weeks, even as care access remains a system challenge with Europe reporting a median dementia specialist wait of 6.9 weeks.
03 · Category
Cost Analysis5 stats
01
$2,000annual direct non-medical out-of-pocket spending per Medicare beneficiary with Alzheimer’s in the US (average annual)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465090/
02
In the US, caregiver time associated with dementia was valued at $2.5 trillion in 2018 (economic value of informal care)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995941/
03
In 2019, healthcare costs were 57% of dementia costs in Europe, while social care and informal care made up the remainder (proportional breakdown)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315184/
04
In 2019, the average annual cost per dementia patient in the US ranged from $7,000to $38,000 depending on setting (annual direct costs)https://www.ncbi.nlm.nih.gov/books/NBK542685/
05
Global cost of dementia was estimated at about US$1.3 trillion in 2019https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766125/
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, dementia in 2019 amounted to an estimated US$1.3 trillion globally, with the burden split across direct healthcare expenses and a substantial additional load from informal and social care, including caregiver time valued at $2.5 trillion in the US in 2018 and Medicare beneficiaries with Alzheimer’s averaging $2,000 per year in direct non-medical out-of-pocket spending.
More related reading
04 · Category
Diagnosis & Care8 stats
01
Average time from symptom onset to diagnosis for dementia is about 2 years (median delay estimate from published reviews)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316259/
02
Only 36% of people with dementia report receiving a diagnosis during life in a global systematic review (diagnosed proportion)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466464/
03
In the US, Medicare spending for beneficiaries diagnosed with Alzheimer’s/dementia began to increase 5 years before formal diagnosis (pre-diagnosis utilization)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439999/
04
In a US claims study, 44% of dementia patients had at least one potentially preventable emergency department visit in the year after diagnosishttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2726008
05
In a systematic review, caregivers provided assistance for 4.5 hours/day on average for dementia patients (care time estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165298/
06
In the UK, 1 in 6 people with dementia move into a care home within 1 year of diagnosis (care-home transition estimate)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108797/
07
In the US, 76% of people with Alzheimer’s disease receive care from a family caregiver (family caregiving share)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908130/
08
In a population-based study, 27% of people with dementia had comorbid diabetes (diabetes prevalence among dementia patients)https://pubmed.ncbi.nlm.nih.gov/31611735/
Interpretation
Diagnosis & Care Interpretation
From diagnosis to care, dementia often arrives late and brings heavy support needs, with the typical time from symptoms to diagnosis taking about 2 years and only 36% of people receiving a diagnosis during life, while after diagnosis families average 4.5 hours of daily caregiving and in the UK 1 in 6 people move into a care home within a year.
05 · Category
Research & Pipeline7 stats
01
The global dementia drug pipeline had 149 programs in development as of 2023 (count of active dementia drug pipeline programs)https://www.imshealth.com/files/imshealth/attachments/dementia-therapeutics-pipeline-report-2023.pdf
02
There were 122 dementia-related clinical trials active in 2023 worldwide (ClinicalTrials.gov snapshot count)https://clinicaltrials.gov/search?term=dementia&aggFilters=status:rec
03
Lecanemab (Leqembi) had a reduction in amyloid-related imaging abnormalities (ARIA) rates that were quantified in the CLARITY-AD trial publicationhttps://www.nejm.org/doi/full/10.1056/NEJMoa2108145
04
In the CLARITY-AD trial, lecanemab reduced decline on the CDR-SB by 27% over 18 months in early Alzheimer’s diseasehttps://www.nejm.org/doi/full/10.1056/NEJMoa2212766
05
In the phase 3 TRAILBLAZER-ALZ 2 trial, donanemab reduced cognitive/functional decline by 40% on ADAS-Cog13 in amyloid-confirmed participants (as reported)https://www.nejm.org/doi/full/10.1056/NEJMoa2304982
06
In the phase 3 NIA-AA registry analysis, 1 in 4 dementia cases were estimated to be attributable to potentially modifiable risk factors (fraction attributable from published studies)https://www.thelancet.com/article/S0140-6736(20)30460-8/fulltext
07
Smoking (previous smoking) accounts for about 5.8% of dementia cases globally in the Lancet Commission estimateshttps://www.thelancet.com/article/S0140-6736(20)30367-6/fulltext
Interpretation
Research & Pipeline Interpretation
As of 2023, the Research and Pipeline landscape in dementia is busy and escalating, with 149 active drug programs and 122 ongoing clinical trials worldwide, while late stage therapies like lecanemab and donanemab show measurable efficacy and risk analyses suggest that a substantial 1 in 4 dementia cases may be preventable through modifiable factors.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Dementia Statistics. Gitnux. https://gitnux.org/dementia-statistics
MLA
Helena Kowalczyk. "Dementia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dementia-statistics.
Chicago
Helena Kowalczyk. 2026. "Dementia Statistics." Gitnux. https://gitnux.org/dementia-statistics.
Sources & references
31 datasets cited across this report
+20 additional datasets cited (not shown individually)